'Victorious Youth', also known as the Getty Bronze, has been the object of a long legal fight
Reported by Independent 5 hours ago.
Getty museum ordered to return 2000-year-old ancient Greek statue by Italy Supreme Court
↧
↧
Italy's far-right minister Matteo Salvini admonished by prosecutor for tweeting about Nigerian 'mafiosi' arrests
Police operations threatened by interior minister's social media habit, prosecutor claims
Reported by Independent 5 hours ago.
↧
$543 Million Triple Negative Breast Cancer (TNBC) Market Insight, Epidemiology and Market Forecast, 2027
Dublin, Dec. 05, 2018 (GLOBE NEWSWIRE) -- The "Triple Negative Breast Cancer (TNBC) - Market Insight, Epidemiology and Market Forecast" drug pipelines has been added to *ResearchAndMarkets.com's* offering.
The Triple Negative Breast Cancer (TNBC) - Market Insight, Epidemiology and Market Forecast-2027' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of TNBC in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), Japan and China.
The report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Triple Negative Breast Cancer (TNBC) from 2016 to 2027 segmented by G8 markets. The report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
*Triple Negative Breast Cancer (TNBC) - Disease Understanding and Treatment Algorithm*
The Triple Negative Breast Cancer (TNBC) market report gives the thorough understanding of the Triple Negative Breast Cancer by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Triple Negative Breast Cancer in the US, Europe, Japan and China.
*Triple Negative Breast Cancer Epidemiology*
The Triple Negative Breast Cancer (TNBC) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every G8 Countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.
This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total diagnosed incident cases and sub-type specific incident cases) scenario of Triple Negative Breast Cancer (TNBC) in the G8 Countries covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom), Japan and China from 2016-2027.
The total number of diagnosed incident population of Triple Negative Breast Cancer (TNBC) was found to be 123,914 in the year 2016.
*Triple Negative Breast Cancer Drug Chapters*This segment of the Triple Negative Breast Cancer report encloses the detailed analysis of marketed drugs and late stage (Registration, Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details of each included drug and the latest news and press releases.
At present, systemic chemotherapy remains the mainstay for the treatment of TNBC due to lack of targeted therapies and contributes towards the market size of TNBC. The several therapeutic classes of the drugs include DNA repair complex like (platinum compounds and taxanes), p53 like (taxanes), cell proliferation like (anthracycline containing regimen) and targeted therapy. Detailed chapter for upcoming therapies like Sacituzumab Govitecan (Immunomedics), Atezolizumab (Roche), Pembrolizumab (Merck), Ipatasertib (Roche), Enzalutamide (Pfizer/Astellas), Cobimetinib (Roche), Rucaparib (Clovis Oncology), Niraparib (Tesaro) and Capitasertib (AstraZeneca) have been covered in the report.
*Triple Negative Breast Cancer Market Outlook*
The Triple Negative Breast Cancer market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
The market of Triple Negative Breast Cancer in G8 Countries was found to be USD 0.543 billion in 2016, and is expected to increase from 2016-2027.*
*
*Key Topics Covered:**1. Key Insights*
*2. Triple Negative Breast Cancer Market Overview at a Glance*
2.1. Market Share (%) Distribution of Triple Negative Breast Cancer in 2016
2.2. Market Share (%) Distribution of Triple Negative Breast Cancer in 2027
*3. Disease Background and Overview: Triple Negative Breast Cancer*
3.1. Introduction
3.2. Types of Breast Cancer
3.3. Risk factors
3.4. Molecular Subtypes in Triple Negative Breast Cancer
3.5. Mutations Associated with Triple Negative Breast Cancer
3.6. Pathogenesis
3.7. Signs and Symptoms
3.8. Diagnosis
3.9. Diagnostic Guidelines
3.10. Stages of Triple Negative Breast Cancer
3.11. Molecular Markers for TNBC and Basal-like Breast Cancer
*4. Unmet Needs*
*5. Epidemiology and Patient Population*
5.1. Key Findings
5.2. Population and Forecast Parameters
5.3. Total Diagnosed Incident Cases of TNBC in G8 countries
*6. Country Wise-Epidemiology of TNBC*
*7. Treatment Practices*
7.1. Treatment
7.2. Treatment Guidelines
*8. Marketed Drug Analysis*
8.1. Lynparza: AstraZeneca
*9. Emerging Therapies*
9.1. Emerging Drugs Analysis
9.1.1. Sacituzumab Govitecan: Immunomedics
9.2. Atezolizumab: Roche
9.3. Pembrolizumab: Merck
9.4. Ipatasertib: Roche
9.5. Enzalutamide: Pfizer/Astellas
9.6. Cobimetinib: Hoffman La Roche
9.7. Rucaparib: Clovis Oncology
9.8. Niraparib: Tesaro
9.9. Capivasertib: AstraZeneca
*10. Triple Negative Breast Cancer [TNBC]: G8 Countries Market Analysis*
10.1. Key Findings
10.2. Total Market Size of Triple Negative Breast Cancer (TNBC) in G8 Countries
10.3. G8 Countries Market Size of TNBC by First Line of Therapies
10.4. G8 Countries Market Size of TNBC by Second Line of Therapies
*11. Market Outlook by Country*
*12. Market Drivers*
*13. Market Barriers*
*14. Appendix*
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/wdnddl/543_million?w=12
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Breast Cancer Drugs Reported by GlobeNewswire 5 hours ago.
The Triple Negative Breast Cancer (TNBC) - Market Insight, Epidemiology and Market Forecast-2027' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of TNBC in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), Japan and China.
The report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Triple Negative Breast Cancer (TNBC) from 2016 to 2027 segmented by G8 markets. The report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
*Triple Negative Breast Cancer (TNBC) - Disease Understanding and Treatment Algorithm*
The Triple Negative Breast Cancer (TNBC) market report gives the thorough understanding of the Triple Negative Breast Cancer by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Triple Negative Breast Cancer in the US, Europe, Japan and China.
*Triple Negative Breast Cancer Epidemiology*
The Triple Negative Breast Cancer (TNBC) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every G8 Countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.
This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total diagnosed incident cases and sub-type specific incident cases) scenario of Triple Negative Breast Cancer (TNBC) in the G8 Countries covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom), Japan and China from 2016-2027.
The total number of diagnosed incident population of Triple Negative Breast Cancer (TNBC) was found to be 123,914 in the year 2016.
*Triple Negative Breast Cancer Drug Chapters*This segment of the Triple Negative Breast Cancer report encloses the detailed analysis of marketed drugs and late stage (Registration, Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details of each included drug and the latest news and press releases.
At present, systemic chemotherapy remains the mainstay for the treatment of TNBC due to lack of targeted therapies and contributes towards the market size of TNBC. The several therapeutic classes of the drugs include DNA repair complex like (platinum compounds and taxanes), p53 like (taxanes), cell proliferation like (anthracycline containing regimen) and targeted therapy. Detailed chapter for upcoming therapies like Sacituzumab Govitecan (Immunomedics), Atezolizumab (Roche), Pembrolizumab (Merck), Ipatasertib (Roche), Enzalutamide (Pfizer/Astellas), Cobimetinib (Roche), Rucaparib (Clovis Oncology), Niraparib (Tesaro) and Capitasertib (AstraZeneca) have been covered in the report.
*Triple Negative Breast Cancer Market Outlook*
The Triple Negative Breast Cancer market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
The market of Triple Negative Breast Cancer in G8 Countries was found to be USD 0.543 billion in 2016, and is expected to increase from 2016-2027.*
*
*Key Topics Covered:**1. Key Insights*
*2. Triple Negative Breast Cancer Market Overview at a Glance*
2.1. Market Share (%) Distribution of Triple Negative Breast Cancer in 2016
2.2. Market Share (%) Distribution of Triple Negative Breast Cancer in 2027
*3. Disease Background and Overview: Triple Negative Breast Cancer*
3.1. Introduction
3.2. Types of Breast Cancer
3.3. Risk factors
3.4. Molecular Subtypes in Triple Negative Breast Cancer
3.5. Mutations Associated with Triple Negative Breast Cancer
3.6. Pathogenesis
3.7. Signs and Symptoms
3.8. Diagnosis
3.9. Diagnostic Guidelines
3.10. Stages of Triple Negative Breast Cancer
3.11. Molecular Markers for TNBC and Basal-like Breast Cancer
*4. Unmet Needs*
*5. Epidemiology and Patient Population*
5.1. Key Findings
5.2. Population and Forecast Parameters
5.3. Total Diagnosed Incident Cases of TNBC in G8 countries
*6. Country Wise-Epidemiology of TNBC*
*7. Treatment Practices*
7.1. Treatment
7.2. Treatment Guidelines
*8. Marketed Drug Analysis*
8.1. Lynparza: AstraZeneca
*9. Emerging Therapies*
9.1. Emerging Drugs Analysis
9.1.1. Sacituzumab Govitecan: Immunomedics
9.2. Atezolizumab: Roche
9.3. Pembrolizumab: Merck
9.4. Ipatasertib: Roche
9.5. Enzalutamide: Pfizer/Astellas
9.6. Cobimetinib: Hoffman La Roche
9.7. Rucaparib: Clovis Oncology
9.8. Niraparib: Tesaro
9.9. Capivasertib: AstraZeneca
*10. Triple Negative Breast Cancer [TNBC]: G8 Countries Market Analysis*
10.1. Key Findings
10.2. Total Market Size of Triple Negative Breast Cancer (TNBC) in G8 Countries
10.3. G8 Countries Market Size of TNBC by First Line of Therapies
10.4. G8 Countries Market Size of TNBC by Second Line of Therapies
*11. Market Outlook by Country*
*12. Market Drivers*
*13. Market Barriers*
*14. Appendix*
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/wdnddl/543_million?w=12
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Breast Cancer Drugs Reported by GlobeNewswire 5 hours ago.
↧
Italy's far-right government forces migrants to leave shelters ahead of Christmas
New law established by Matteo Salvini abolishes 'humanitarian protection' status for asylum seekers
Reported by Independent 4 hours ago.
↧
Chemotherapy-Induced Peripheral Neuropathy (CIPN) Report 2018 - Market Insights, Epidemiology and Market Forecast, 2016-2027
Dublin, Dec. 05, 2018 (GLOBE NEWSWIRE) -- The "Chemotherapy-Induced Peripheral Neuropathy (CIPN) - Market Insights, Epidemiology and Market Forecast" drug pipelines has been added to *ResearchAndMarkets.com's* offering.The Chemotherapy-Induced Peripheral Neuropathy (CIPN) - Market Insights, Epidemiology and Market Forecast-2027' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of CIPN in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), Japan and China.
The report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Chemotherapy-Induced Peripheral Neuropathy from 2016 to 2027 segmented by eight major markets. The report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
*Chemotherapy-Induced Peripheral Neuropathy - Disease Understanding and Treatment Algorithm*
Chemotherapy-induced peripheral neuropathy (CIPN) is a frequent, dose-dependent complication of anticancer drugs, including platinums, taxanes, epothilones, vinca alkaloids, and newer agents, such as bortezomib. It not only leads to dose reduction or discontinuation of treatment but also decreases the quality of life of cancer survivors.
With the exception of paclitaxel and oxaliplatin, which cause an acute neuropathy that emerges either during or shortly after infusion, the onset of CIPN is usually delayed and appears to depend on the total cumulative dose. Clinically, CIPN presents as deficits in sensory, motor, and autonomic function which develop in a compound-specific manner.
The Chemotherapy-Induced Peripheral Neuropathy (CIPN) market report gives the thorough understanding of the CIPN by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for CIPN in the US, Europe, Japan and China.
*Chemotherapy-Induced Peripheral Neuropathy Epidemiology*
The Chemotherapy-Induced Peripheral Neuropathy epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 8 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.
This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented by Total Incident Population of CIPN, Severity Specific Incident Population of CIPN and Incident Population of CIPN by Chemotherapeutic Agents] scenario of Chemotherapy-Induced Peripheral Neuropathy in the G8 countries covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom), Japan and China from 2016-2027.
According to the publisher, incident population of CIPN in the G8 countries is expected to increase at a CAGR of 0.35% for the study period i.e. 2016-2027. The publisher estimates show higher incidence of CIPN in China with 1,542,149 cases in 2016, due to the higher incidence of cancer than US, EU5 and Japan.
Among the European countries, Germany had the highest incident population of CIPN, followed by the United Kingdom in 2016. On the other hand, Spain had the lowest incident population of nearly 80,000 in 2016. According to the report, majority of the CIPN cases is caused by the platinum-based chemotherapeutic agents such as oxaliplatin and cisplatin, followed by taxane agents.
Furthermore, assessments show that in terms of severity, the majority of the patients have been diagnosed with moderate and severe forms of CIPN, while mild CIPN cases were also diagnosed. In 2016, incident cases of mild, moderate and severe CIPN in the US varied in the range 100,000 to 300,000. This trend is expected to be followed during the forecast period [2018-2027].
*Chemotherapy-Induced Peripheral Neuropathy Drug Chapters*
This segment of the Chemotherapy-Induced Peripheral Neuropathy (CIPN) report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
The market size of CIPN depends entirely on the type of nerve damage, symptoms, and location. Currently, there is no approved therapy for the treatment of CIPN. The current therapeutic landscape of CIPN worldwide is dependent on off-label therapies, used to reduce the symptoms in CIPN patients.
Guidelines for the prevention and management of CIPN in survivors of adult cancers, have reported pharmacologic treatment of neuropathic pain developed with a consensus that alpha-2-delta antagonist (anticonvulsants), serotonin-norepinephrine re-uptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), opioids, and topical analgesics are good treatment options for neuropathic pain.
Detailed chapters of upcoming therapies such as SP-04 (PledOx; Solasia), Tetrodotoxin (TTX; WEX Pharmaceuticals) and E-52862 (Esteve), which are expected to launch during the forecast period [2018-2027] have also been covered in the report.
*Chemotherapy-Induced Peripheral Neuropathy Market Outlook*
The Chemotherapy-Induced Peripheral Neuropathy (CIPN) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
The market size of Chemotherapy Induced Peripheral Neuropathy (CIPN) in the G8 Countries is expected to increase at a CAGR of 2.94% for the study period (2016-2027). Expected launch of potential therapies may increase the market size in the coming years, assisted by an increase in the incident population of CIPN.
Among the different classes of therapies which are currently prescribed to patients with CIPN, opioid analgesics is the most prescribed one that led to highest market size among other classes. China accounts for the highest market size of CIPN in comparison to the United States, the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.
*Chemotherapy-Induced Peripheral Neuropathy Drugs Uptake*
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Many companies are aggressively working towards the development of targeted therapies for CIPN such as PledOx/Solasia, WEX Pharmaceuticals, Asahi Kasei, MediciNova, Achelios Therapeutics, Esteve, ChromaDex, Apollo Endosurgery (Lpath), Hoffmann-La Roche, Midatech/DARA, Lee's Pharmaceutical Limited, Novartis, Relief Therapeutics and others. Of the aforementioned pharmaceutical companies, targeted products by Solasia (SP-04), WEX Pharmaceuticals (Tetrodotoxin) and Esteve (E-52862) are expected to be launched during the forecast period [2018-2027].
It has been assessed that SP-04 holds the highest expectations of analysts. Despite the launch E-52862 (Esteve) later than Tetrodotoxin (TTX; WEX Pharmaceuticals), E-52862 is predicted to create comparatively greater impact on the market size of CIPN. This may be attributed to the target-specific mechanism of E-52862 for CIPN, while Tetrodotoxin will be launched by WEX Pharmaceuticals, for overall neuropathic pain.
*Chemotherapy-Induced Peripheral Neuropathy Report Insights*
· Patient Population
· Therapeutic Approaches
· Pipeline Analysis
· Market Size and Trends
· Market Opportunities
· Impact of upcoming Therapies
*Chemotherapy-Induced Peripheral Neuropathy Report Key Strengths*
· 10 Years Forecast
· G8 Coverage
· Epidemiology Segmentation
· Key Cross Competition
· Market Size by Therapies
· Drugs Uptake
*Chemotherapy-Induced Peripheral Neuropathy Report Assessment*
· Pipeline Product Profiles
· Key Products and Key Players
· Market Drivers and Barriers
*Key Benefits*
· This report will help to develop Business Strategies by understanding the trends shaping and driving Chemotherapy-Induced Peripheral Neuropathy market
· Organize sales and marketing efforts by identifying the best opportunities for Chemotherapy-Induced Peripheral Neuropathy market
· To understand the future market competition in the Chemotherapy-Induced Peripheral Neuropathy market.
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/r8ckr4/chemotherapyinduc?w=12
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Central Nervous System Drugs Reported by GlobeNewswire 4 hours ago.
The report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Chemotherapy-Induced Peripheral Neuropathy from 2016 to 2027 segmented by eight major markets. The report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
*Chemotherapy-Induced Peripheral Neuropathy - Disease Understanding and Treatment Algorithm*
Chemotherapy-induced peripheral neuropathy (CIPN) is a frequent, dose-dependent complication of anticancer drugs, including platinums, taxanes, epothilones, vinca alkaloids, and newer agents, such as bortezomib. It not only leads to dose reduction or discontinuation of treatment but also decreases the quality of life of cancer survivors.
With the exception of paclitaxel and oxaliplatin, which cause an acute neuropathy that emerges either during or shortly after infusion, the onset of CIPN is usually delayed and appears to depend on the total cumulative dose. Clinically, CIPN presents as deficits in sensory, motor, and autonomic function which develop in a compound-specific manner.
The Chemotherapy-Induced Peripheral Neuropathy (CIPN) market report gives the thorough understanding of the CIPN by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for CIPN in the US, Europe, Japan and China.
*Chemotherapy-Induced Peripheral Neuropathy Epidemiology*
The Chemotherapy-Induced Peripheral Neuropathy epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 8 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.
This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented by Total Incident Population of CIPN, Severity Specific Incident Population of CIPN and Incident Population of CIPN by Chemotherapeutic Agents] scenario of Chemotherapy-Induced Peripheral Neuropathy in the G8 countries covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom), Japan and China from 2016-2027.
According to the publisher, incident population of CIPN in the G8 countries is expected to increase at a CAGR of 0.35% for the study period i.e. 2016-2027. The publisher estimates show higher incidence of CIPN in China with 1,542,149 cases in 2016, due to the higher incidence of cancer than US, EU5 and Japan.
Among the European countries, Germany had the highest incident population of CIPN, followed by the United Kingdom in 2016. On the other hand, Spain had the lowest incident population of nearly 80,000 in 2016. According to the report, majority of the CIPN cases is caused by the platinum-based chemotherapeutic agents such as oxaliplatin and cisplatin, followed by taxane agents.
Furthermore, assessments show that in terms of severity, the majority of the patients have been diagnosed with moderate and severe forms of CIPN, while mild CIPN cases were also diagnosed. In 2016, incident cases of mild, moderate and severe CIPN in the US varied in the range 100,000 to 300,000. This trend is expected to be followed during the forecast period [2018-2027].
*Chemotherapy-Induced Peripheral Neuropathy Drug Chapters*
This segment of the Chemotherapy-Induced Peripheral Neuropathy (CIPN) report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
The market size of CIPN depends entirely on the type of nerve damage, symptoms, and location. Currently, there is no approved therapy for the treatment of CIPN. The current therapeutic landscape of CIPN worldwide is dependent on off-label therapies, used to reduce the symptoms in CIPN patients.
Guidelines for the prevention and management of CIPN in survivors of adult cancers, have reported pharmacologic treatment of neuropathic pain developed with a consensus that alpha-2-delta antagonist (anticonvulsants), serotonin-norepinephrine re-uptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), opioids, and topical analgesics are good treatment options for neuropathic pain.
Detailed chapters of upcoming therapies such as SP-04 (PledOx; Solasia), Tetrodotoxin (TTX; WEX Pharmaceuticals) and E-52862 (Esteve), which are expected to launch during the forecast period [2018-2027] have also been covered in the report.
*Chemotherapy-Induced Peripheral Neuropathy Market Outlook*
The Chemotherapy-Induced Peripheral Neuropathy (CIPN) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
The market size of Chemotherapy Induced Peripheral Neuropathy (CIPN) in the G8 Countries is expected to increase at a CAGR of 2.94% for the study period (2016-2027). Expected launch of potential therapies may increase the market size in the coming years, assisted by an increase in the incident population of CIPN.
Among the different classes of therapies which are currently prescribed to patients with CIPN, opioid analgesics is the most prescribed one that led to highest market size among other classes. China accounts for the highest market size of CIPN in comparison to the United States, the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.
*Chemotherapy-Induced Peripheral Neuropathy Drugs Uptake*
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Many companies are aggressively working towards the development of targeted therapies for CIPN such as PledOx/Solasia, WEX Pharmaceuticals, Asahi Kasei, MediciNova, Achelios Therapeutics, Esteve, ChromaDex, Apollo Endosurgery (Lpath), Hoffmann-La Roche, Midatech/DARA, Lee's Pharmaceutical Limited, Novartis, Relief Therapeutics and others. Of the aforementioned pharmaceutical companies, targeted products by Solasia (SP-04), WEX Pharmaceuticals (Tetrodotoxin) and Esteve (E-52862) are expected to be launched during the forecast period [2018-2027].
It has been assessed that SP-04 holds the highest expectations of analysts. Despite the launch E-52862 (Esteve) later than Tetrodotoxin (TTX; WEX Pharmaceuticals), E-52862 is predicted to create comparatively greater impact on the market size of CIPN. This may be attributed to the target-specific mechanism of E-52862 for CIPN, while Tetrodotoxin will be launched by WEX Pharmaceuticals, for overall neuropathic pain.
*Chemotherapy-Induced Peripheral Neuropathy Report Insights*
· Patient Population
· Therapeutic Approaches
· Pipeline Analysis
· Market Size and Trends
· Market Opportunities
· Impact of upcoming Therapies
*Chemotherapy-Induced Peripheral Neuropathy Report Key Strengths*
· 10 Years Forecast
· G8 Coverage
· Epidemiology Segmentation
· Key Cross Competition
· Market Size by Therapies
· Drugs Uptake
*Chemotherapy-Induced Peripheral Neuropathy Report Assessment*
· Pipeline Product Profiles
· Key Products and Key Players
· Market Drivers and Barriers
*Key Benefits*
· This report will help to develop Business Strategies by understanding the trends shaping and driving Chemotherapy-Induced Peripheral Neuropathy market
· Organize sales and marketing efforts by identifying the best opportunities for Chemotherapy-Induced Peripheral Neuropathy market
· To understand the future market competition in the Chemotherapy-Induced Peripheral Neuropathy market.
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/r8ckr4/chemotherapyinduc?w=12
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Central Nervous System Drugs Reported by GlobeNewswire 4 hours ago.
↧
↧
Autism Spectrum Disorder (ASD) Pipeline Report 2018: Market Insights, Epidemiology and Market Forecast 2016-2027
Dublin, Dec. 05, 2018 (GLOBE NEWSWIRE) -- The "Autism Spectrum Disorder (ASD) - Market Insights, Epidemiology and Market Forecast-2027" drug pipelines has been added to *ResearchAndMarkets.com's* offering.
Autism Spectrum Disorder (ASD) - Market Insights, Epidemiology and Market Forecast-2027' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Autism Spectrum Disorder (ASD) in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Autism Spectrum Disorder (ASD) from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
*Geography Covered*
· The United States
· EU5 (Germany, France, Italy, Spain and the United Kingdom)
· Japan
*Study Period:* 2016-2027
*Autism Spectrum Disorder (ASD) - Disease Understanding and Treatment Algorithm*
Autism Spectrum Disorder (ASD) is a developmental disorder that affects communication and behavior. Although autism can be diagnosed at any age, it is said to be a developmental disorder because symptoms generally appear in the first two years of life. ASD refers to a group of neurodevelopmental conditions defined by impairment in three areas: social interaction, communication or use of verbal and non-verbal language, and a stereotyped, restricted or repetitive pattern of behavior, interests and activities.
Autism Spectrum Disorder (ASD) is used to be called as Pervasive Developmental Disorder (PDD). PDD included five types or categories: Autistic Disorder, Asperger's Disorder, Childhood Disintegrative Disorder, Rett's Syndrome, and pervasive developmental Disorder-Not Otherwise Specified (PDD-NOS).
The Autism Spectrum Disorder (ASD) market report gives the thorough understanding of the ASD by including details such as disease definition, classification, Etiology, Pathophysiology, Signs and Symptoms and diagnostic trends. It also provides treatment algorithms and treatment guidelines for Autism Spectrum Disorder (ASD) in the US, Europe, and Japan.
*Autism Spectrum Disorder Epidemiology*
The Autism Spectrum Disorder epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented as Total Diagnosed Prevalent Cases of Autism Spectrum Disorder (ASD), Gender Specific Diagnosed Prevalent Cases of Autism Spectrum Disorder (ASD) and Subtype-Specific Diagnosed Prevalent Cases of Autism Spectrum Disorder (ASD)] scenario of ASD in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom), and Japan from 2016-2027.
As per the study conducted by Guifeng Xu et al., titled as Prevalence of Autism Spectrum Disorder among US Children and Adolescents, 2014-2016, the estimated prevalence for Autism Spectrum Disorder was 2.47% among US children and adolescents in 2014-2016, with no statistically significant increase over the 3 years. The observed prevalence was higher than estimates in previous years from the ADDM, although differences in study design and participant characteristics may partly explain the prevalence differences.
The total 7MM prevalent cases of Autism Spectrum Disorder in 2016 were 6,545,050 out of which the highest prevalent cases of this disease were seen in the United States, which accounted for approximately 57% of the total prevalent cases. The EU5 countries accounted for 1,715,717 cases as a whole in 2016. Japan had 1,094,393 cases in 2016, which accounted for approximately 17% of the total 7MM prevalent cases of Autism Spectrum Disorder. The total prevalent cases of ASD in 7MM is calculated by adding the prevalent cases of the individual country.
According to this research, total prevalent population of Autism Spectrum Disorder (ASD) in the 7 major markets is estimated approximately 6,545,050 cases in 2016 and it is expected to be change during the forecasted period (2016-2027).
This research estimates that the prevalent population of Autism Spectrum Disorder (ASD) in 7MM is expected to change for the study period 2016-2027.
This research estimates a higher prevalence of Autism Spectrum Disorder (ASD) in the United States with 3,734,939 cases in 2016.
*Autism Spectrum Disorder Drug Chapters*
This segment of the Autism Spectrum Disorder (ASD) report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
The current therapeutic market for Autism Spectrum Disorder (ASD) is being dependent on the two FDA approved products including Johnson's Risperdal and Otsuka's Abilify and one EMA approved Neurim's Slenyto. Other off-label therapies are also being used to improve the signs and symptoms of the disease. Drugs commonly prescribed to Autism Spectrum Disorder (ASD) patients include antipsychotics, antidepressants, selective-serotonin reuptake inhibitors, stimulants, anticonvulsants, antihypertensives, CNS depressants and others.
Key players such as Roche, Neurochlore/Servier, Optinose, Yamo Pharmaceuticals, Curemark, etc. are developing emerging therapies for the treatment of patients with Autism Spectrum Disorder (ASD). Expected launch of emerging therapies such as Balovaptan (Roche), Bumetanide (Neurochlore/Servier), OPN-300 (Optinose), L1-79 (Yamo Pharmaceuticals), CM-AT (Curemark), are expected to increase the market size of ASD in upcoming years.
*Autism Spectrum Disorder (ASD) Market Outlook*
The Autism Spectrum Disorder (ASD) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to this research, the market of Autism Spectrum Disorder (ASD) in 7MM was found to be USD 2510.2 million in 2016, and is expected to increase from 2016-2027.
The United States accounts for the largest Autism Spectrum Disorder (ASD) market size, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain), and Japan.
*Autism Spectrum Disorder (ASD) Drugs Uptake*
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
*Autism Spectrum Disorder (ASD) Report Insights*
· Patient Population
· Therapeutic Approaches
· Pipeline Analysis
· Market Size and Trends
· Market Opportunities
· Impact of upcoming Therapies
*Autism Spectrum Disorder (ASD) Report Key Strengths*
· 10 Years Forecast
· 7MM Coverage
· Epidemiology Segmentation
· Key Cross Competition
· Highly Analyzed Market
· Drugs Uptake
*ASD Report Assessment*
· Current Treatment Practices
· Unmet Needs
· Pipeline Product Profiles
· Market Attractiveness
· Market Drivers and Barriers
*Key Benefits*
· This report will help to develop Business Strategies by understanding the trends shaping and driving Autism Spectrum Disorder (ASD) market
· Organize sales and marketing efforts by identifying the best opportunities for Autism Spectrum Disorder (ASD) market
· To understand the future market competition in the Autism Spectrum Disorder (ASD) market.
*Companies Mentioned *· Roche
· Neurochlore/Servier
· Curemark
· Yamo Pharmaceuticals
· Johnson and Johnson
· Otsuka Pharmaceutical
· Neurim Pharmaceuticals
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/r3xnhv/autism_spectrum?w=12
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Central Nervous System Drugs Reported by GlobeNewswire 4 hours ago.
Autism Spectrum Disorder (ASD) - Market Insights, Epidemiology and Market Forecast-2027' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Autism Spectrum Disorder (ASD) in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Autism Spectrum Disorder (ASD) from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
*Geography Covered*
· The United States
· EU5 (Germany, France, Italy, Spain and the United Kingdom)
· Japan
*Study Period:* 2016-2027
*Autism Spectrum Disorder (ASD) - Disease Understanding and Treatment Algorithm*
Autism Spectrum Disorder (ASD) is a developmental disorder that affects communication and behavior. Although autism can be diagnosed at any age, it is said to be a developmental disorder because symptoms generally appear in the first two years of life. ASD refers to a group of neurodevelopmental conditions defined by impairment in three areas: social interaction, communication or use of verbal and non-verbal language, and a stereotyped, restricted or repetitive pattern of behavior, interests and activities.
Autism Spectrum Disorder (ASD) is used to be called as Pervasive Developmental Disorder (PDD). PDD included five types or categories: Autistic Disorder, Asperger's Disorder, Childhood Disintegrative Disorder, Rett's Syndrome, and pervasive developmental Disorder-Not Otherwise Specified (PDD-NOS).
The Autism Spectrum Disorder (ASD) market report gives the thorough understanding of the ASD by including details such as disease definition, classification, Etiology, Pathophysiology, Signs and Symptoms and diagnostic trends. It also provides treatment algorithms and treatment guidelines for Autism Spectrum Disorder (ASD) in the US, Europe, and Japan.
*Autism Spectrum Disorder Epidemiology*
The Autism Spectrum Disorder epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented as Total Diagnosed Prevalent Cases of Autism Spectrum Disorder (ASD), Gender Specific Diagnosed Prevalent Cases of Autism Spectrum Disorder (ASD) and Subtype-Specific Diagnosed Prevalent Cases of Autism Spectrum Disorder (ASD)] scenario of ASD in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom), and Japan from 2016-2027.
As per the study conducted by Guifeng Xu et al., titled as Prevalence of Autism Spectrum Disorder among US Children and Adolescents, 2014-2016, the estimated prevalence for Autism Spectrum Disorder was 2.47% among US children and adolescents in 2014-2016, with no statistically significant increase over the 3 years. The observed prevalence was higher than estimates in previous years from the ADDM, although differences in study design and participant characteristics may partly explain the prevalence differences.
The total 7MM prevalent cases of Autism Spectrum Disorder in 2016 were 6,545,050 out of which the highest prevalent cases of this disease were seen in the United States, which accounted for approximately 57% of the total prevalent cases. The EU5 countries accounted for 1,715,717 cases as a whole in 2016. Japan had 1,094,393 cases in 2016, which accounted for approximately 17% of the total 7MM prevalent cases of Autism Spectrum Disorder. The total prevalent cases of ASD in 7MM is calculated by adding the prevalent cases of the individual country.
According to this research, total prevalent population of Autism Spectrum Disorder (ASD) in the 7 major markets is estimated approximately 6,545,050 cases in 2016 and it is expected to be change during the forecasted period (2016-2027).
This research estimates that the prevalent population of Autism Spectrum Disorder (ASD) in 7MM is expected to change for the study period 2016-2027.
This research estimates a higher prevalence of Autism Spectrum Disorder (ASD) in the United States with 3,734,939 cases in 2016.
*Autism Spectrum Disorder Drug Chapters*
This segment of the Autism Spectrum Disorder (ASD) report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
The current therapeutic market for Autism Spectrum Disorder (ASD) is being dependent on the two FDA approved products including Johnson's Risperdal and Otsuka's Abilify and one EMA approved Neurim's Slenyto. Other off-label therapies are also being used to improve the signs and symptoms of the disease. Drugs commonly prescribed to Autism Spectrum Disorder (ASD) patients include antipsychotics, antidepressants, selective-serotonin reuptake inhibitors, stimulants, anticonvulsants, antihypertensives, CNS depressants and others.
Key players such as Roche, Neurochlore/Servier, Optinose, Yamo Pharmaceuticals, Curemark, etc. are developing emerging therapies for the treatment of patients with Autism Spectrum Disorder (ASD). Expected launch of emerging therapies such as Balovaptan (Roche), Bumetanide (Neurochlore/Servier), OPN-300 (Optinose), L1-79 (Yamo Pharmaceuticals), CM-AT (Curemark), are expected to increase the market size of ASD in upcoming years.
*Autism Spectrum Disorder (ASD) Market Outlook*
The Autism Spectrum Disorder (ASD) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to this research, the market of Autism Spectrum Disorder (ASD) in 7MM was found to be USD 2510.2 million in 2016, and is expected to increase from 2016-2027.
The United States accounts for the largest Autism Spectrum Disorder (ASD) market size, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain), and Japan.
*Autism Spectrum Disorder (ASD) Drugs Uptake*
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
*Autism Spectrum Disorder (ASD) Report Insights*
· Patient Population
· Therapeutic Approaches
· Pipeline Analysis
· Market Size and Trends
· Market Opportunities
· Impact of upcoming Therapies
*Autism Spectrum Disorder (ASD) Report Key Strengths*
· 10 Years Forecast
· 7MM Coverage
· Epidemiology Segmentation
· Key Cross Competition
· Highly Analyzed Market
· Drugs Uptake
*ASD Report Assessment*
· Current Treatment Practices
· Unmet Needs
· Pipeline Product Profiles
· Market Attractiveness
· Market Drivers and Barriers
*Key Benefits*
· This report will help to develop Business Strategies by understanding the trends shaping and driving Autism Spectrum Disorder (ASD) market
· Organize sales and marketing efforts by identifying the best opportunities for Autism Spectrum Disorder (ASD) market
· To understand the future market competition in the Autism Spectrum Disorder (ASD) market.
*Companies Mentioned *· Roche
· Neurochlore/Servier
· Curemark
· Yamo Pharmaceuticals
· Johnson and Johnson
· Otsuka Pharmaceutical
· Neurim Pharmaceuticals
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/r3xnhv/autism_spectrum?w=12
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Central Nervous System Drugs Reported by GlobeNewswire 4 hours ago.
↧
Italy's coalition spreads confusion over vaccinations by sacking commission of health experts
Reported by Telegraph.co.uk 3 hours ago.
↧
Serie A to stage Supercoppa match in Saudi Arabia
MILAN (Reuters) - Italy's Supercoppa match between Juventus and AC Milan will be staged in Saudi Arabia next month, the Serie A league said in a statement on Wednesday.
Reported by SBS 3 hours ago.
↧
EUR/USD: Dollar’s advantage to recede - UBS
In the forecast report for 2019, the Investment Research Team at UBS, expect the greenback to retain its strength in the near term, but they think the dollar is likely to depreciate over time as policy normalization gets underway in Europe.
*Key Quotes: *
“The USD remains overvalued thanks to marked positive short-term interest rate differentials as the Federal Reserve continues to raise interest rates. This state of affairs, along with the dispute over Italy’s budget, is likely to prompt further near-term gains for the USD relative to the EUR.”
“Looking further ahead, we expect the Fed to near the end of its rate-hiking cycle in 2019, while the European Central Bank (ECB) will only be starting to normalize interest rates, which will cause the differentials to shrink and the dollar’s advantage to recede, in our view.”
“The support for US growth from fiscal stimulus will also wane next year, and the US twin fiscal and current account deficits are likely to start to weigh on the dollar.”
“We forecast EURUSD at 1.15 and 1.20 over six and 12 months. A key risk to our view is the US launching a large infrastructure program, which could boost growth and inflation. The dollar could also remain stronger relative to the euro if US-China trade frictions intensify in 2019, Eurozone data slows, or the ECB appoints a dovish successor to current president Mario Draghi.”
Reported by FXstreet.com 3 hours ago.
*Key Quotes: *
“The USD remains overvalued thanks to marked positive short-term interest rate differentials as the Federal Reserve continues to raise interest rates. This state of affairs, along with the dispute over Italy’s budget, is likely to prompt further near-term gains for the USD relative to the EUR.”
“Looking further ahead, we expect the Fed to near the end of its rate-hiking cycle in 2019, while the European Central Bank (ECB) will only be starting to normalize interest rates, which will cause the differentials to shrink and the dollar’s advantage to recede, in our view.”
“The support for US growth from fiscal stimulus will also wane next year, and the US twin fiscal and current account deficits are likely to start to weigh on the dollar.”
“We forecast EURUSD at 1.15 and 1.20 over six and 12 months. A key risk to our view is the US launching a large infrastructure program, which could boost growth and inflation. The dollar could also remain stronger relative to the euro if US-China trade frictions intensify in 2019, Eurozone data slows, or the ECB appoints a dovish successor to current president Mario Draghi.”
Reported by FXstreet.com 3 hours ago.
↧
↧
EUR/JPY recovers toward mid-128s, looks to close day higher following upbeat data
· *Retail sales in the euro area rebound in November. *
· *Services PMI reading surpasses market expectation.*
· *Italy's Di Maio says the climate is changing in budget talks.*
After losing more than 100 pips on Tuesday with the JPY gathering strength on flight-to-safety, the EUR/JPY pair staged a recovery and rose toward the mid-128s. As of writing, the pair was trading at 128.43, adding 0.4% on a daily basis,
Earlier today, the data released by the Eurostat showed that retail sales in the euro area increased 0.3% in October following September's 0.5% decline and surpassed the analysts' estimate for a 0.2% growth. Furthermore, the IHS Markit's Services PMI came in at 53.4 to beat the market expectation of 53.1 to provide an additional boost to the shared currency.
On the other hand, fears over the U.S. Treasury yield curve inversion, which is seen as an early sign of a possible recession, eased on Wednesday and forced the JPY to lose some market interest. However, today's price action seems to be a technical correction and the JPY could continue to find demand as a safe-haven if Wall Street and T-bond yields extend their slide tomorrow when markets re-open.
*Technical levels to consider*
The initial resistance for the pair aligns at 129 (Dec. 4 high) ahead of 129.40 (Dec. 3 high) and 130 (psychological level). On the downside, supports are located 127.80 (Dec. 5 low), 127.20 (Oct. 29 low) and 126.60 (Oct. 26 low). Reported by FXstreet.com 3 hours ago.
· *Services PMI reading surpasses market expectation.*
· *Italy's Di Maio says the climate is changing in budget talks.*
After losing more than 100 pips on Tuesday with the JPY gathering strength on flight-to-safety, the EUR/JPY pair staged a recovery and rose toward the mid-128s. As of writing, the pair was trading at 128.43, adding 0.4% on a daily basis,
Earlier today, the data released by the Eurostat showed that retail sales in the euro area increased 0.3% in October following September's 0.5% decline and surpassed the analysts' estimate for a 0.2% growth. Furthermore, the IHS Markit's Services PMI came in at 53.4 to beat the market expectation of 53.1 to provide an additional boost to the shared currency.
On the other hand, fears over the U.S. Treasury yield curve inversion, which is seen as an early sign of a possible recession, eased on Wednesday and forced the JPY to lose some market interest. However, today's price action seems to be a technical correction and the JPY could continue to find demand as a safe-haven if Wall Street and T-bond yields extend their slide tomorrow when markets re-open.
*Technical levels to consider*
The initial resistance for the pair aligns at 129 (Dec. 4 high) ahead of 129.40 (Dec. 3 high) and 130 (psychological level). On the downside, supports are located 127.80 (Dec. 5 low), 127.20 (Oct. 29 low) and 126.60 (Oct. 26 low). Reported by FXstreet.com 3 hours ago.
↧
Police arrest 84 in crackdown on Italian mob
Hundreds of police in Germany, Italy, Belgium and the Netherlands arrested at least 84 suspected mobsters and seized around 2 million euros (NZ$3.3 million) Wednesday in a series of coordinated raids targeting a powerful Italian organised...
Reported by New Zealand Herald 3 hours ago.
↧
European market wrap up: Brexit might not happen at all, FTSE plunges on troubled UK politics and shocking services data
· *In European markets, the two standouts, for opposites, were Italy that outperformed due to 'positive' progress on a budget agreement with the EU while for the UK, Brexit continued to create just about enough angst in government concerns to send the FTSE lower that was also weighed by some pretty shocking services data. *
· *In France, the CAC 40 continues to be troubled by political challenges and public unrest, despite Macron caving in under the pressures and backing down on the gas tax. *
European markets are still feeling the heat following a switch up in sentient surrounding global growth prospects and global trade relations. At the same time, the political environment is as uncertain as ever, on both mainland Europe and Britain. While there may have been some clarity found today over legalities over Article 50, it still does not bode well for UK politics and the future of the Conservative party.
*Closing percentage changes for European indexes*
· UK FTSE 100 -1.44%
· German DAX -1.19%
· French CAC -1.36%
· Italy MIB -0.1%
· Spain IBEX -0.55%
Germany stocks were in the doldrums again on Wednesday with the Technology, Insurance and Software sectors weighing on Frankfurt's major index. The DAX dropped 1.19% with the worst of the index coming from Wirecard AG which dropped 2.67% or by 3.700 points to trade at 134.850 by the end of the session. Infineon Technologies AG NA O.N.fell 2.39% or 0.450 points to end at 18.355 and Fresenius Medical Care KGAA ST dropped 2.18% or 1.600 points to 71.720. Helping to support the index was Heidelbergcement AG O.N. which added 0.46% or 0.260 points to trade at 57.360 and Bayer AG NA also rose 0.43% or by 0.28 points to finish the day at 65.61. RWE AG ST O.N. added 0.41% or 0.080 points to 19.390 by the close.
*Brexit draws **most** attention*
The main news came from London on Wednesday. UK multinationals shares were weighed by a strong pound while the FTSE 100 was down 1.1% at 6,943.23 as Brexit angst continues to linger despite some positives have come of recent legal advice which could mean that Brexit may not happen at all. As for shares, housebuilders rallied, with Berkeley, Barratt Developments, Persimmon and Taylor Wimpey the top four performing stocks on the FTSE 100 as the prospect of a second referendum became more real.
UK P May's the government was defeated on two contempt of Parliament motions for not publishing the full legal advice on the withdrawal agreement. Backbenchers approved an amendment which gives them a greater say if the Brexit proposal is defeated in next week's meaningful vote.
Should parliament not support any deal before the Article 50 window expires, the chances of leaving without a deal are greatly reduced. It also raises the prospect of the UK not leaving at all should the public vote against it this time around in a second referendum. JPMorgan upped its odds on the possibility of Britain remaining in the EU to 40% from 20% and said it now sees the chances of a no-deal Brexit at 10%, reduced from 20%, and an orderly Brexit at 50% now versus 60% before. Comments from pro-Brexit International Trade Secretary Liam Fox also provided a boost, as he told a parliamentary committee that no Brexit was now a possibility.
As for the performers, Berkeley Group Holdings (The) (BKG) 3,485.00p 7.89%. Barratt Developments (BDEV) 479.90p 6.46% and Persimmon (PSN) 1,978.46p 6.14%. The non-performers were Ashtead Group (AHT) 1,683.50p -5.21%. Reckitt Benckiser Group (RB.) 6,401.00p -3.32%. Hargreaves Lansdown (HL.) 1,914.00p -3.28%
*UK Services data shocker*
Activity in the UK's services sector for November was reported to have softened to its weakest level for more than two years in November. Confidence levels also slumped due to Brexit angst. IHS Markit/CIPS UK services purchasing managers' index dropped from October's reading of 52.2 to 50.4, the lowest since July 2016. A reading below 50 indicates a contraction - A number of services sector companies said Brexit had prompted clients to delay investment decision, and there had been a slowdown in new business growth. There has now been a slowdown in new business growth for three consecutive months. Confidence for the year ahead showed the weakest degree of positive sentiment since July 2016.
*Technical levels*
*FTSE:*
The FTSE is negative on the charts with long bodied candlesticks that point to further downside as the bears remain in control will little in the way coming in from the bulls at this stage of the week, so far. The price is testing the barrier s of the daily Bollinger bands and the prior November lows, which could bring in some support. However, daily RSI has room to go until overbought conditions might encourage a buy-in or paring of shorts on profit taking and the next target is the S1 pivot point located at 6888. A break there opens YTD lows of 6850 and then S2 at 6820 and S3 at 6715. On the flipside, the pivot point is located at 6993 and above the daily high of 6977. 7016 was a prior low with the confluence of the 50-4hr SMA which guards the 21-4hr SMA at 7022. R1 is located at 7061 and the 2018 range 23.6% level is located at 7100. The 38.2% Fibo of 2018's range at 7262 is the primary objective thereafter.
*DAX:*
We have a bearish bias on the charts still with the index consolidating below the gap after yesterday's drop. The index is in the lower end of the Bollinger bands and below the descending 21-D SMA now located at 11344. A break of the recent lows of 11141 leaves scope for a run to the 11007 level as the 19th Nov low. 10860 comes as the 2016 Aug-Nov level as the critical downside target. Bulls need to get back above the 50-D SMA at 11559 ahead of the 23.6% Fibo target at 11617. Reported by FXstreet.com 3 hours ago.
· *In France, the CAC 40 continues to be troubled by political challenges and public unrest, despite Macron caving in under the pressures and backing down on the gas tax. *
European markets are still feeling the heat following a switch up in sentient surrounding global growth prospects and global trade relations. At the same time, the political environment is as uncertain as ever, on both mainland Europe and Britain. While there may have been some clarity found today over legalities over Article 50, it still does not bode well for UK politics and the future of the Conservative party.
*Closing percentage changes for European indexes*
· UK FTSE 100 -1.44%
· German DAX -1.19%
· French CAC -1.36%
· Italy MIB -0.1%
· Spain IBEX -0.55%
Germany stocks were in the doldrums again on Wednesday with the Technology, Insurance and Software sectors weighing on Frankfurt's major index. The DAX dropped 1.19% with the worst of the index coming from Wirecard AG which dropped 2.67% or by 3.700 points to trade at 134.850 by the end of the session. Infineon Technologies AG NA O.N.fell 2.39% or 0.450 points to end at 18.355 and Fresenius Medical Care KGAA ST dropped 2.18% or 1.600 points to 71.720. Helping to support the index was Heidelbergcement AG O.N. which added 0.46% or 0.260 points to trade at 57.360 and Bayer AG NA also rose 0.43% or by 0.28 points to finish the day at 65.61. RWE AG ST O.N. added 0.41% or 0.080 points to 19.390 by the close.
*Brexit draws **most** attention*
The main news came from London on Wednesday. UK multinationals shares were weighed by a strong pound while the FTSE 100 was down 1.1% at 6,943.23 as Brexit angst continues to linger despite some positives have come of recent legal advice which could mean that Brexit may not happen at all. As for shares, housebuilders rallied, with Berkeley, Barratt Developments, Persimmon and Taylor Wimpey the top four performing stocks on the FTSE 100 as the prospect of a second referendum became more real.
UK P May's the government was defeated on two contempt of Parliament motions for not publishing the full legal advice on the withdrawal agreement. Backbenchers approved an amendment which gives them a greater say if the Brexit proposal is defeated in next week's meaningful vote.
Should parliament not support any deal before the Article 50 window expires, the chances of leaving without a deal are greatly reduced. It also raises the prospect of the UK not leaving at all should the public vote against it this time around in a second referendum. JPMorgan upped its odds on the possibility of Britain remaining in the EU to 40% from 20% and said it now sees the chances of a no-deal Brexit at 10%, reduced from 20%, and an orderly Brexit at 50% now versus 60% before. Comments from pro-Brexit International Trade Secretary Liam Fox also provided a boost, as he told a parliamentary committee that no Brexit was now a possibility.
As for the performers, Berkeley Group Holdings (The) (BKG) 3,485.00p 7.89%. Barratt Developments (BDEV) 479.90p 6.46% and Persimmon (PSN) 1,978.46p 6.14%. The non-performers were Ashtead Group (AHT) 1,683.50p -5.21%. Reckitt Benckiser Group (RB.) 6,401.00p -3.32%. Hargreaves Lansdown (HL.) 1,914.00p -3.28%
*UK Services data shocker*
Activity in the UK's services sector for November was reported to have softened to its weakest level for more than two years in November. Confidence levels also slumped due to Brexit angst. IHS Markit/CIPS UK services purchasing managers' index dropped from October's reading of 52.2 to 50.4, the lowest since July 2016. A reading below 50 indicates a contraction - A number of services sector companies said Brexit had prompted clients to delay investment decision, and there had been a slowdown in new business growth. There has now been a slowdown in new business growth for three consecutive months. Confidence for the year ahead showed the weakest degree of positive sentiment since July 2016.
*Technical levels*
*FTSE:*
The FTSE is negative on the charts with long bodied candlesticks that point to further downside as the bears remain in control will little in the way coming in from the bulls at this stage of the week, so far. The price is testing the barrier s of the daily Bollinger bands and the prior November lows, which could bring in some support. However, daily RSI has room to go until overbought conditions might encourage a buy-in or paring of shorts on profit taking and the next target is the S1 pivot point located at 6888. A break there opens YTD lows of 6850 and then S2 at 6820 and S3 at 6715. On the flipside, the pivot point is located at 6993 and above the daily high of 6977. 7016 was a prior low with the confluence of the 50-4hr SMA which guards the 21-4hr SMA at 7022. R1 is located at 7061 and the 2018 range 23.6% level is located at 7100. The 38.2% Fibo of 2018's range at 7262 is the primary objective thereafter.
*DAX:*
We have a bearish bias on the charts still with the index consolidating below the gap after yesterday's drop. The index is in the lower end of the Bollinger bands and below the descending 21-D SMA now located at 11344. A break of the recent lows of 11141 leaves scope for a run to the 11007 level as the 19th Nov low. 10860 comes as the 2016 Aug-Nov level as the critical downside target. Bulls need to get back above the 50-D SMA at 11559 ahead of the 23.6% Fibo target at 11617. Reported by FXstreet.com 3 hours ago.
↧
Tiemoue Bakayoko: AC Milan want Chelsea misfit on permanent basis following dramatic transformation
AC Milan are looking to sign Chelsea midfielder Tiemoue Bakayoko on a permanent basis as he continues to impress on loan in Italy. The Frenchman, who struggled in his debut season at Stamford Bridge, has received three consecutive man-of-the-match awards in Serie A. And Milan, who have a £31million option to buy, have been so […]
Reported by talkSPORT 3 hours ago.
↧
↧
Moscow asks Italy to drop charges against Russian in Nigeria graft case
The Russian government has asked Italy to be "reasonable" over a Russian citizen caught up in a Nigerian graft case in Milan and drop the charges against him, according to legal documents seen by Reuters.
Reported by Reuters 2 hours ago.
↧
Suspected mafia members arrested in coordinated international raids
Police arrested dozens of suspected mobsters in Europe and South America on Wednesday in a huge international swoop targeting Italy's notorious 'Ndrangheta mafia clan, officials said.
Reported by France 24 2 hours ago.
↧
The Father, the Son and the Sins of Italian Politics
Luigi Di Maio, Italy’s squeaky clean deputy prime minister, has long tarred opponents with the alleged misdeeds of their fathers. Now his father is under scrutiny.
Reported by NYTimes.com 1 hour ago.
↧
LIVE SCORES: All the goals as they go in
Follow games in the UK, Spain, Italy, Germany, France and beyond with Goal's extensive match coverage!
Reported by Goal.com 1 hour ago.
↧
↧
From Coimbra to Vieira de Leiria in the City of Marinha Grande in Portugal Follows the International Art Exhibition of Surrealism Now 2019
*Open January 26 of 2019 and Stands for Indefinite Duration in the Municipal Gallery of Vieira de Leiria in the Municipality of Marinha Grande*Marinha Grande, Portugal, Dec. 05, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- The International Surrealism Now is the world's largest surrealist exhibition in the 21th century. presenting so far 117 of the main surrealist artists from 49 countries of the five continents, continuing its work this time in the city of Marinha Grande in the Municipal Gallery of Vieira de Leiria, after having already passed through the cities of Lisbon, Porto, Setubal, Amadora , Lousã, Aveiro, Coimbra, Conimbriga Museum and in the Medieval Castle of Ega's palace.
This ground breaking project is presented by Santiago Ribeiro, Portuguese surrealist painter, dedicated to promoting Surrealism of the 21st century, through exhibitions presented over the last 8 years in various parts of the world: Berlin, Moscow, Dallas, Los Angeles, Mississippi, Warsaw, Nantes, Paris, London, Florence, Madrid, Granada, Barcelona, Lisbon, Belgrade, Monte Negro, Romania, Japan, Taiwan and Brazil.
*Note: *The renowned cultural magazine, *The Culture Trip *, named 10 Portuguese artists as the most internationally recognized at the present time and Santiago Ribeiro is one of them.
Ribeiro's work has been featured at the *U.S. Embassy in Lisbon *, in the *Portuguese American Journal *, in *Digital Meets Culture *, *Pressenza fr *, *metroNews.ru *, *Pravda in Portuguese *, *The Herald News *, *ARTVOICE *, *Associated Press *, *EFE* , *APA ots,* *AAP *, *Reuters *, *ANA *, *News Aktuell and many other publications can be seeing on the link.*
*His sponsors include Coimbra House Mayor, Bissaya Barreto Foundation and MagicCraftsman Studio.*
He conceived the International Surrealism Now movement in 2010 in Coimbra with a major exhibit organized by Bissaya Barreto.
Billed as the largest world exhibition of contemporary Surrealism art in Europe – with more than 100 artists from about 50 countries participating – the exhibit of paintings, drawings, digital art, photographs and sculpture is also expected to be shown, at least in part, at several monuments and public spaces throughout Portugal.
International Surrealism Now of the 21st century presents a strong force for freedom of creativity, love and hope. This can be seen in the works of the personal visions of 116 of the world’s leading surrealism artists representing the hopes, dreams and ideologies of 49 countries proposing new perspectives, solutions and healing journeys.
Showcasing the dreams of creative and ideological freedom, the modern day internet allows us to bring you the vital works of these astounding 21st century surrealist artists.
*Artists:*
*Achraf Baznani*, Morocco / *Agim Meta*, Spain / *Aissa Mammasse*, Algeria / *Alessio Serpetti*, Italy / *Alvaro Mejias*, Venezuela / *Ana Neamu*,Romania / *Ana Pilar Morales*,* *Spain / *Andrew Baines*, Australia / *Aquilino Ferreira*, Portugal / *Asier Guerrero Rico* (Dio), Spain / *Brigid Marlin*,UK / *Bien Banez*, Philippines / *Can Emed*, Turkey / *Carlos Sablón*, Cuba / *Cătălin Precup*, Romania / *Cristian Townsend*, Australia / *Conor Walton*, Ireland / *Cynthia Tom*, China / USA / *Dag Samsund*, Denmark / *Daila Lupo*, Italy / *Dan Neamu*, Romania / *Daniel Chiriac*, Romania / *Daniel Hanequand,* France / Canada / *Daniele Gori*, Italy / *Delphine Cencig*, France / *Dean Fleming*, USA / *Domen Lo*, Slovenia / *Edgar Invoker*, Russia / *Efrat Cybulkiewicz*, Venezuela / *Egill Eibsen*, Iceland / *Erik Heyninck*, Belgium / *Ettore Aldo Del Vigo*, Italy / *Farhad Jafari*, Iran / *France Garrido*, USA / *Francisco Urbano*, Portugal / *Genesis Cabrera*, USA / *Graça Bordalo Pinheiro*, Portugal / *Graszka Paulska*, Poland / *Gromyko Semper*, Philippines / *Gyuri Lohmuller*, Romania / *Hector Pineda*, Mexico / *Hector Toro*, Colombia / *Henrietta Kozica*, Sweden / *Hugues Gillet*, France / *Isabel Meyrelles*, Portugal / *Iwasaki Nagi*, Japan / *James Skelton*, UK / *Jay Garfinkle*, USA / *Jay Paul Vonkoffler*, American / Argentine / *Jimah St*, Nigeria / *Joanna Budzyńska-Sycz, *Poland / *João Duarte*, Portugal / *Keith Wigdor*, USA / *Leo Wijnhoven*, Netherlands / *Leo Plaw*,Germany / *Liba WS*, France / *Lubomír Štícha*, Republic Czech / *Ludgero Rolo*, Portugal / *Lv Shang*, China / *Maarten Vet*, Netherlands / *Maciej Hoffman*, Poland / *Magi Calhoun*, USA / *Marnie Pitts*, UK / *Maria Aristova*, Russia / *Mario Devcic*, Croatia / *Martina Hoffman*, Germany / *Mathias Böhm*, Germany / *Mehriban Efendi*, Azerbaijan / *Naiker Roman*, Cuba / Spain / *Nazareno Stanislau*, Brazil / *Nikolina Petolas*, Croatia / *Octavian Florescu*, Canada / *Ofelia Hutul*, Romania / *Oleg Korolev*, Russia / *Olesya Novik*, Russia / *Olga Spiegel*, USA / *Otto Rapp*, Austria / *Paula Rosa*,Portugal / *Paulo Cunha*, Canada / *Pedro Diaz Cartes*, Chile / *Penny Golledge*, UK / *Peter MC LANE*, France / *Philippe Pelletier*, France / *Roch Fautch,* USA / *Rodica Miller, *USA* */ *Ruben Cukier*, Argentine / Israeli / *Rudolf Boelee*, New Zealand / *Russbelt Guerra,* Peru / *Sabina Nore*,Austria / *Sampo Kaikkonen*, Finland / *Santiago Ribeiro*, Portugal / *Sarah Zambiasi,* Australia / *Serge Sunne,* Latvia / *Sergey Tyukanov*, Russia / *Shahla Rosa*, USA / *Shoji Tanaka*, Japan / *Shan Zhulan*, China / *Shia Weltenmenge,* Germany / *Sio Shisio*, Indonesia / *Slavko Krunic*, Serbia / *Sônia Menna Barreto*, Brazil / *Steve Smith*, USA / *Stuart Griggs*, UK / *Svetlana Kislyachenko*, Ukraine / *Svetlana Ratova*, Russia / *Tatomir Pitariu*, USA / *Tersanszki Cornelia*, Romania / *Ton Haring*, Netherlands / *Victor Lages*, Portugal / *Vu Huyen Thuong*, Vietnam / *Yamal Din*,Morocco / Spain / *Yuliya Patotskaya*, Belarus / *Yuri Tsvetaev*, Russia / *Zoltan Ducsai*, Hungary / *Zoran Velimanovic*, Serbia.
*49 countries: Algeria, Argentina, Australia, Austria, Azerbaijan, Belarus, Belgium, Brazil, Canada, Chile, China, Colombia, Croatia, Czech Republic, Cuba, Denmark, Finland, France, Germany, Hungary, Iceland, Indonesia, Iran, Ireland, Israel, Italy, Japan, Latvia, Mexico, Morocco, Netherlands, New Zealand, Nigeria, Peru, Philippines, Poland, Portugal, Romania, Russia, Serbia, Slovenia, Spain, Sweden, Turkey, United Kingdom, United States, Ukraine, Venezuela, Vietnam.*
*Municipal Gallery of Vieira de Leiria*
*Contacts*
Email:
international@surrealismnow.pl
*Phone:
+351 239718541*
www.facebook.com/internationalsurrealismnow.org
*Address:** *Galeria Municipal Tony Vitorino, Cine-Teatro Actor Álvaro, Largo da República, Vieira de Leiria, Marinha Grande, Portugal.
*Attachment*
· International Surrealism Now Reported by GlobeNewswire 1 hour ago.
This ground breaking project is presented by Santiago Ribeiro, Portuguese surrealist painter, dedicated to promoting Surrealism of the 21st century, through exhibitions presented over the last 8 years in various parts of the world: Berlin, Moscow, Dallas, Los Angeles, Mississippi, Warsaw, Nantes, Paris, London, Florence, Madrid, Granada, Barcelona, Lisbon, Belgrade, Monte Negro, Romania, Japan, Taiwan and Brazil.
*Note: *The renowned cultural magazine, *The Culture Trip *, named 10 Portuguese artists as the most internationally recognized at the present time and Santiago Ribeiro is one of them.
Ribeiro's work has been featured at the *U.S. Embassy in Lisbon *, in the *Portuguese American Journal *, in *Digital Meets Culture *, *Pressenza fr *, *metroNews.ru *, *Pravda in Portuguese *, *The Herald News *, *ARTVOICE *, *Associated Press *, *EFE* , *APA ots,* *AAP *, *Reuters *, *ANA *, *News Aktuell and many other publications can be seeing on the link.*
*His sponsors include Coimbra House Mayor, Bissaya Barreto Foundation and MagicCraftsman Studio.*
He conceived the International Surrealism Now movement in 2010 in Coimbra with a major exhibit organized by Bissaya Barreto.
Billed as the largest world exhibition of contemporary Surrealism art in Europe – with more than 100 artists from about 50 countries participating – the exhibit of paintings, drawings, digital art, photographs and sculpture is also expected to be shown, at least in part, at several monuments and public spaces throughout Portugal.
International Surrealism Now of the 21st century presents a strong force for freedom of creativity, love and hope. This can be seen in the works of the personal visions of 116 of the world’s leading surrealism artists representing the hopes, dreams and ideologies of 49 countries proposing new perspectives, solutions and healing journeys.
Showcasing the dreams of creative and ideological freedom, the modern day internet allows us to bring you the vital works of these astounding 21st century surrealist artists.
*Artists:*
*Achraf Baznani*, Morocco / *Agim Meta*, Spain / *Aissa Mammasse*, Algeria / *Alessio Serpetti*, Italy / *Alvaro Mejias*, Venezuela / *Ana Neamu*,Romania / *Ana Pilar Morales*,* *Spain / *Andrew Baines*, Australia / *Aquilino Ferreira*, Portugal / *Asier Guerrero Rico* (Dio), Spain / *Brigid Marlin*,UK / *Bien Banez*, Philippines / *Can Emed*, Turkey / *Carlos Sablón*, Cuba / *Cătălin Precup*, Romania / *Cristian Townsend*, Australia / *Conor Walton*, Ireland / *Cynthia Tom*, China / USA / *Dag Samsund*, Denmark / *Daila Lupo*, Italy / *Dan Neamu*, Romania / *Daniel Chiriac*, Romania / *Daniel Hanequand,* France / Canada / *Daniele Gori*, Italy / *Delphine Cencig*, France / *Dean Fleming*, USA / *Domen Lo*, Slovenia / *Edgar Invoker*, Russia / *Efrat Cybulkiewicz*, Venezuela / *Egill Eibsen*, Iceland / *Erik Heyninck*, Belgium / *Ettore Aldo Del Vigo*, Italy / *Farhad Jafari*, Iran / *France Garrido*, USA / *Francisco Urbano*, Portugal / *Genesis Cabrera*, USA / *Graça Bordalo Pinheiro*, Portugal / *Graszka Paulska*, Poland / *Gromyko Semper*, Philippines / *Gyuri Lohmuller*, Romania / *Hector Pineda*, Mexico / *Hector Toro*, Colombia / *Henrietta Kozica*, Sweden / *Hugues Gillet*, France / *Isabel Meyrelles*, Portugal / *Iwasaki Nagi*, Japan / *James Skelton*, UK / *Jay Garfinkle*, USA / *Jay Paul Vonkoffler*, American / Argentine / *Jimah St*, Nigeria / *Joanna Budzyńska-Sycz, *Poland / *João Duarte*, Portugal / *Keith Wigdor*, USA / *Leo Wijnhoven*, Netherlands / *Leo Plaw*,Germany / *Liba WS*, France / *Lubomír Štícha*, Republic Czech / *Ludgero Rolo*, Portugal / *Lv Shang*, China / *Maarten Vet*, Netherlands / *Maciej Hoffman*, Poland / *Magi Calhoun*, USA / *Marnie Pitts*, UK / *Maria Aristova*, Russia / *Mario Devcic*, Croatia / *Martina Hoffman*, Germany / *Mathias Böhm*, Germany / *Mehriban Efendi*, Azerbaijan / *Naiker Roman*, Cuba / Spain / *Nazareno Stanislau*, Brazil / *Nikolina Petolas*, Croatia / *Octavian Florescu*, Canada / *Ofelia Hutul*, Romania / *Oleg Korolev*, Russia / *Olesya Novik*, Russia / *Olga Spiegel*, USA / *Otto Rapp*, Austria / *Paula Rosa*,Portugal / *Paulo Cunha*, Canada / *Pedro Diaz Cartes*, Chile / *Penny Golledge*, UK / *Peter MC LANE*, France / *Philippe Pelletier*, France / *Roch Fautch,* USA / *Rodica Miller, *USA* */ *Ruben Cukier*, Argentine / Israeli / *Rudolf Boelee*, New Zealand / *Russbelt Guerra,* Peru / *Sabina Nore*,Austria / *Sampo Kaikkonen*, Finland / *Santiago Ribeiro*, Portugal / *Sarah Zambiasi,* Australia / *Serge Sunne,* Latvia / *Sergey Tyukanov*, Russia / *Shahla Rosa*, USA / *Shoji Tanaka*, Japan / *Shan Zhulan*, China / *Shia Weltenmenge,* Germany / *Sio Shisio*, Indonesia / *Slavko Krunic*, Serbia / *Sônia Menna Barreto*, Brazil / *Steve Smith*, USA / *Stuart Griggs*, UK / *Svetlana Kislyachenko*, Ukraine / *Svetlana Ratova*, Russia / *Tatomir Pitariu*, USA / *Tersanszki Cornelia*, Romania / *Ton Haring*, Netherlands / *Victor Lages*, Portugal / *Vu Huyen Thuong*, Vietnam / *Yamal Din*,Morocco / Spain / *Yuliya Patotskaya*, Belarus / *Yuri Tsvetaev*, Russia / *Zoltan Ducsai*, Hungary / *Zoran Velimanovic*, Serbia.
*49 countries: Algeria, Argentina, Australia, Austria, Azerbaijan, Belarus, Belgium, Brazil, Canada, Chile, China, Colombia, Croatia, Czech Republic, Cuba, Denmark, Finland, France, Germany, Hungary, Iceland, Indonesia, Iran, Ireland, Israel, Italy, Japan, Latvia, Mexico, Morocco, Netherlands, New Zealand, Nigeria, Peru, Philippines, Poland, Portugal, Romania, Russia, Serbia, Slovenia, Spain, Sweden, Turkey, United Kingdom, United States, Ukraine, Venezuela, Vietnam.*
*Municipal Gallery of Vieira de Leiria*
*Contacts*
Email:
international@surrealismnow.pl
*Phone:
+351 239718541*
www.facebook.com/internationalsurrealismnow.org
*Address:** *Galeria Municipal Tony Vitorino, Cine-Teatro Actor Álvaro, Largo da República, Vieira de Leiria, Marinha Grande, Portugal.
*Attachment*
· International Surrealism Now Reported by GlobeNewswire 1 hour ago.
↧
Three Premier League games to look forward to this Christmas
Unlike the other top-flight European leagues in Spain, Germany and Italy, who take time off from playing games in anticipation of the upcoming January transfer window, the Premier League is renowned for its fans’ excitement and anticipation of the games during the festive period. However, with the growing influence of foreign managers and players, the […]
The post Three Premier League games to look forward to this Christmas appeared first on The Sport Review. Reported by The Sport Review 52 minutes ago.
The post Three Premier League games to look forward to this Christmas appeared first on The Sport Review. Reported by The Sport Review 52 minutes ago.
↧
Uffizi aims to slash tourist crowds, stop ticket scalpers
ROME (AP) — The Uffizi Galleries have turned to algorithm experts in hopes of slashing crowds bunching up in front of the likes of masterpieces by Leonardo and Botticelli and drastically reducing the lines that form outside Italy's most-visited art museum. It's also intent on combatting another persistent problem, ticket scalpers. Director Eike Schmidt told foreign correspondents in Rome on Wednesday that Uffizi officials have been meeting with the government office that protects citizen privacy on devising ways that purchasers' ID photos could be used to thwart scalpers looking to resell tickets at exorbitant prices.
Reported by SeattlePI.com 1 hour ago.
↧
More Pages to Explore .....
